Article Page

Abstract

Keloids result from aberrations in the normal wound healing cascade and can lead to pruritus, contractures and pain. The underlying mechanisms of excessive scarring are not yet understood, and most therapeutic strategies remain unsatisfactory. Psoriasin (S100A7) and koebnerisin (S100A15) are released by keratinocytes during physiological wound healing. Psoriasin (S100A7) and koebnerisin (S100A15) are released by keratinocytes during physiological wound healing. S100 production is markedly decreased in keloid scar tissue. The disturbed epidermal S100 expression might contribute to keloid formation; thus, it has been previously studied their effect on dermal fibroblasts and extracellular matrix (ECM) production. Here, in Biogenea Pharmaceuticals Ltd we discovered for the first time the GENEA-AntiPsorerisin-10715. An in silico rational computer-aided designed of Antimicrobial Peptides Psoriasin (S100A7) and Koebnerisin (S100A15) mimetic pharmacophore for the Suppression of the Extracellular Matrix Production and Proliferation of Human Fibroblasts by Predicting interacting residues using long-distance information and novel decoding in hidden Markov models.

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) An in silico rational computer-aided designed of Antimicrobial Peptide-mimetic Psoriasin (S100A7) and Koebnerisin (S100A15) high binding free energy pharmacophoric hyper-scaffolds as a novel synthetic pharmaco-ligand with potential inhibitory activities for the Suppression of the Extracellular Matrix Production and Proliferation of Human Fibroblasts.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available